Massachusetts 2025-2026 Regular Session

Massachusetts Senate Bill S1400

Introduced
2/27/25  
Refer
2/27/25  
Refer
9/11/25  
Report Pass
9/30/25  
Refer
10/2/25  

Caption

Authorizing a pilot for the use of psychedelics in licensed treatment facilities

Impact

If enacted, S1400 would empower the Department of Public Health to establish rules and regulations governing the operation of psychedelic treatments in selected clinics. The bill specifically allows for the licensing of up to three facilities that are not affiliated with the cannabis industry or pharmaceutical companies. Each facility must focus exclusively on mental health treatment, highlighting a clear separation from other commercial interests. This move may significantly shift how mental health treatment is approached and bring new options to patients who have not found success with traditional therapies.

Summary

Senate Bill S1400 seeks to initiate a pilot program for the supervised use of psychedelics in licensed mental health treatment facilities within Massachusetts. This bill is presented as a forward-thinking approach to mental health care, proposing that certain clinically appropriate patients will have access to psychedelic therapy under controlled conditions. The bill aims to enhance therapeutic options for individuals facing mental health challenges such as depression, anxiety, PTSD, and substance use disorders.

Contention

There are potential points of contention surrounding S1400, particularly in terms of public perception and regulatory oversight of psychedelic substances. Critics may argue that while there is emerging research supporting the therapeutic potential of psychedelics, concerns over safety, effectiveness, and the ethical implications of their use in a clinical setting could lead to significant pushback. Additionally, the limitations placed on facility operations to those strictly aligned with mental health care—excluding affiliations with the broader cannabis industry—could spark debates regarding access and the broader implications for mental health treatment accessibility in Massachusetts.

Companion Bills

No companion bills found.

Previously Filed As

MA H4200

Authorizing a pilot for the use of psychedelics in licensed treatment facilities

MA S1117

Relative to treatment, not incarceration

MA S1401

To provide more timely treatment of inpatient mental health care

MA S2813

Order relative to authorizing the joint committee on Mental Health, Substance Use and Recovery, to make an investigation and study of certain current Senate documents relative to insurance and treatment matters.

MA HB4014

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

MA SB3005

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

MA AB1090

Alcoholism or drug abuse treatment facilities: County of Orange pilot program.

MA S1635

Authorizing pharmacists to provide opioid use disorder treatment

MA H4473

Authorizing the select board of the town of Arlington to place upon a town ballot a question to increase the number of licenses for all alcoholic beverages not to be drunk on the premises

MA H4986

Relative to therapeutic psilocybin treatment centers

Similar Bills

MD SB336

Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership

MD HB427

Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership

NV SJR10

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)

TX HB4014

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

AZ SB1555

Approved medication; rescheduling; controlled substance

GA HB717

Medical Practice Act; regulation of the administration of psychedelic-assisted treatment and therapy; provide

TX SB3005

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

NJ A1526

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.